Landmark Study Published in The Lancet Oncology Shows Celgene Corporation’s Vidaza(R) Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced the publication in the journal The Lancet Oncology of the results from AZA-001, the largest international, randomized, Phase III study ever conducted in patients with higher-risk myelodysplastic syndromes (MDS). The data indicate that VIDAZA (azacitidine) demonstrated a significant extension of overall survival compared to conventional care regimens (CCR) for patients with Intermediate-2 and high-risk MDS and AML with 20 to 30 percent bone marrow blasts.